We knocked down the HCT116 cell line with high endogenous expression and the results showed that knocking down CCL24 in HCT116 cells resulted in a significant reduction in the tumor burden of mCRC animal model mice, while enhancing the therapeutic effect of Bev treatment in mice (Figure 2K–N). The gene discussed is CCL24; the disease is neoplasm.